At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
C21 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc)
In Brief
A Phase 2 clinical trial evaluating C21 and Placebo for Raynaud Phenomenon and Systemic Sclerosis. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is a randomised, double-blind, placebo-controlled, cross-over phase 2 trial investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud's phenomenon secondary to systemic sclerosis. The purpose of the trial is to achieve a vasodilatory effect in subjects with Raynaud's phenomenon by stimulation of the AT2R (angiotensin II type 2 receptor) with C21.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRaynaud Phenomenon, Systemic Sclerosis
CountriesUnited Kingdom
CollaboratorsSGS Life Sciences, a division of SGS Belgium NV
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
First PostedMay 2020
Primary CompletionDec 2020
TodayJul 2026
First PostedMay 14, 2020
Enrollment StartJan 3, 2020
Primary CompletionDec 14, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.1 years ago
Interventions
C21drug
C21 as first treatment
C21drug
C21 as second treatment
Placebodrug
Placebo as second treatment
Placebodrug
Placebo as first treatment